Skye Bioscience, Inc. $SKYE

By Microcap Ledger desk · CIK 0001516551

Facts as of Oct 11, 2026, 08:18 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: San Diego, CA
Fiscal year end: December 31
Shares outstanding: 35,421,413 [10-Q 2026-08-14]
as of 2026-08-10

Sources: [10-K 2026-03-10]

What the company doesAI summary of filing

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a humanized antibody that modulates the CB1 receptor to treat obesity, overweight, and metabolic disorders. The company makes money through the development and potential commercialization of nimacimab; it is currently pre-revenue and conducting clinical trials, including a Phase 2a study (CBeyond) that showed nimacimab in combination with semaglutide achieved greater weight loss than semaglutide alone. Nimacimab is administered as a subcutaneous injection and is designed to work through peripheral CB1 inhibition rather than central nervous system effects, distinguishing it from previous CB1-targeting approaches. [10-K 2026-03-10]

Segments: Nimacimab (lead candidate, CB1 receptor modulator for obesity and metabolic disorders)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$23.30M	−$15.68M	$8.07M	[10-Q 2026-08-14]
FY ended Dec 2025	—	−$55.92M	−$43.06M	$5.88M	[DEF 14A 2026-04-16]
FY ended Dec 2024	—	−$26.57M	−$25.24M	$68.42M	[DEF 14A 2026-04-16]

Quarterly cash burn: −$7.84M
Cash runway Estimate: ~3.1 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-06	30,338,290	[10-Q 2024-11-07]
2025-03-19	30,974,558	[10-K 2025-03-20]
2025-05-06	30,984,358	[10-Q 2025-05-08]
2025-08-05	30,988,420	[10-Q 2025-08-07]
2025-11-07	32,057,461	[10-Q 2025-11-10]
2026-03-09	33,378,764	[10-K 2026-03-10]
2026-05-08	35,143,722	[10-Q 2026-05-11]
2026-08-10	35,421,413	[10-Q 2026-08-14]

Shelf registration: S-3 filed 2024-05-10; declared effective 2024-05-17 [S-3 2024-05-10]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-19. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-08-19	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-08-19]
2026-05-15	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-05-15]
2026-03-19	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-03-19]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-09-23	Schwab Andrew J.	sell	114,851	$1.61	[4 2026-09-24]
2026-09-23	Schwab Andrew J.	sell	4,528	$1.61	[4 2026-09-24]
2026-09-23	5Am Partners Vii, Llc	sell	114,851	$1.61	[4 2026-09-24]
2026-09-23	5Am Partners Vii, Llc	sell	4,528	$1.61	[4 2026-09-24]
2026-09-22	Schwab Andrew J.	sell	27,612	$1.65	[4 2026-09-24]
2026-09-22	Schwab Andrew J.	sell	1,088	$1.65	[4 2026-09-24]
2026-09-22	5Am Partners Vii, Llc	sell	27,612	$1.65	[4 2026-09-24]
2026-09-22	5Am Partners Vii, Llc	sell	1,088	$1.65	[4 2026-09-24]
2026-09-16	Schwab Andrew J.	sell	32,607	$1.91	[4 2026-09-18]
2026-09-16	Schwab Andrew J.	sell	1,285	$1.91	[4 2026-09-18]
2026-09-16	5Am Partners Vii, Llc	sell	32,607	$1.91	[4 2026-09-18]
2026-09-16	5Am Partners Vii, Llc	sell	1,285	$1.91	[4 2026-09-18]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-24	13D/A	Beneficial ownership report (5%+ holder)
2026-09-11	8-K	Material agreement terminated; Director or officer change; Other events
2026-08-24	8-K	Material agreement entered; Unregistered sale of equity
2026-08-20	8-K	Change to security holder rights
2026-08-19	8-K	Listing notice or transfer
2026-08-18	13D/A	Beneficial ownership report (5%+ holder)
2026-08-14	10-Q	Quarterly report
2026-08-14	8-K	Material agreement entered; Unregistered sale of equity; Change to security holder rights
2026-06-23	8-K	Other events
2026-05-29	8-K	Charter, bylaws or fiscal year change; Shareholder vote results
2026-05-15	8-K	Listing notice or transfer
2026-05-11	10-Q	Quarterly report

Facts as of Oct 11, 2026, 08:18 AM UTC. Small caps move fast; check the latest filings.